Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. (8th February 2015)

• Record Type: Journal Article
• Authors: Arellano, Jorge; Hernandez, Rohini K.; Wade, Sally W.; Chen, Kristina; Pirolli, Melissa; Quach, David; Quigley, Jane; Liede, Alexander; Shahinian, Vahakn B.
• Is Part Of: Cancer medicine. Volume 4:Number 5(2015:May)
• Page Start: 713
• Page End: 720
• Publication Date: 2015-02-08
• Subjects: 616.994005
• DOI: 10.1002/cam4.403
• Languages: English
• ISSNs: 2045-7634

Abstract

<abstract abstract-type="graphical" xml:lang="en" id="cam4403-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p>In patients with bone metastases secondary to solid tumors, the 5‐year prevalence was 43% for renal impairment (RI) and 71% for chronic kidney disease among evaluable RI patients. Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI. <graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgjmx2c45b" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></p> </abstract>